PTC Therapeutics Takes $35M Series E | GenomeWeb

NEW YORK, Jan. 7 (GenomeWeb News) -- PTC Therapeutics of South Plainfield, NJ, announced today the closing of a $35 million Series E round of funding led by CSFB Private Equity and HBM Bioventures.

Additional investors included Bay City Capital, Delphi Ventures, Hansa Special Opportunities Fund Ltd., HealthCap, Novartis BioVentures, Novo A/S, POSCO BioVentures and Vulcan Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.